Department of Neurology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan.
Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan.
BMC Neurol. 2020 Mar 17;20(1):101. doi: 10.1186/s12883-020-01684-6.
Phospholipase A2 group VI (PLA2G6) mutations associated with neurodegeneration (PLAN) manifest as heterogeneous neurodegenerative disorders with variable ages of onset. The genotype-phenotype correlation is not well-established. We aim to describe three adult patients with PLAN and combined these data with results from previous studies to elucidate adult-onset PLA2G6 phenotype-genotype correlations.
The first index patient presented with dystonia-parkinsonism starting at age 31 years, accompanied by major depression and cognitive decline. Genetic analysis using targeted next generation sequencing (NGS) panel, Sanger sequencing, and segregation analyses revealed a compound heterozygous mutation, c.991G > T (p.D331Y)/c.1077G > A (M358IfsX), in PLA2G6. The other two patients had levodopa-responsive, early-onset parkinsonism, starting in their late twenties. Both patients had homozygous c.991G > T (p.D331Y) mutations in PLA2G6. Patient characteristics of our reported 3 cases were compared to those of 32 previously described (2008 to 2019) patients with adult-onset PLAN. Among the combined cohort of 35 patients with adult-onset PLAN, 14 had dystonia-parkinsonism, 17 had early-onset Parkinson's disease, 3 had hereditary spastic paraparesis, and one had ataxia. The c.991G > T (p. D331Y) mutation was almost exclusively found in Chinese patients, suggesting a common founder effect. All patients with homozygous p.D331Y mutations had levodopa-responsive, early-onset PD (100%); while other mutations mostly led to dystonia-parkinsonism, ataxia, spasticity, and combine psychiatric comorbidities.
We showed that adult-onset PLAN could present as purely parkinsonism features, without brain iron accumulation, particularly patients with homozygous p.D331Y mutations. Compound heterozygous mutations, including heterozygous p.D331Y, produced heterogeneous phenotypes, without obvious levodopa responsiveness.
与神经退行性变相关的磷脂酶 A2 组 VI(PLA2G6)突变(PLAN)表现为异质性神经退行性疾病,发病年龄不同。基因型-表型相关性尚未得到很好的确立。我们旨在描述 3 名成年 PLAN 患者,并将这些数据与之前的研究结果相结合,以阐明成年发病 PLA2G6 表型-基因型相关性。
首位索引患者于 31 岁时出现运动障碍性帕金森病,伴有重度抑郁症和认知能力下降。采用靶向下一代测序(NGS)面板、Sanger 测序和分离分析的遗传分析显示 PLA2G6 中存在复合杂合突变 c.991G>T(p.D331Y)/c.1077G>A(M358IfsX)。另外 2 名患者在二十多岁时出现左旋多巴反应性早发性帕金森病。两名患者均在 PLA2G6 中存在纯合 c.991G>T(p.D331Y)突变。我们报告的 3 例患者的特征与 32 例以前描述的(2008 年至 2019 年)成年发病 PLAN 患者进行了比较。在 35 例成年发病 PLAN 患者的联合队列中,14 例有运动障碍性帕金森病,17 例有早发性帕金森病,3 例有遗传性痉挛性截瘫,1 例有共济失调。c.991G>T(p.D331Y)突变几乎仅在中国人中发现,提示存在共同的起源效应。所有携带纯合 p.D331Y 突变的患者均对左旋多巴有反应,且发病早(100%);而其他突变主要导致运动障碍性帕金森病、共济失调、痉挛和合并精神疾病。
我们表明,成年发病 PLAN 可能表现为单纯的帕金森病特征,没有脑铁积累,特别是纯合 p.D331Y 突变的患者。复合杂合突变,包括杂合 p.D331Y,产生了异质性表型,对左旋多巴没有明显的反应性。